Cancer Discov. 2017 Oct;7(10):OF2. doi: 10.1158/2159-8290.CD-NB2017-124. Epub 2017 Sep 6.
Adding a chimeric antigen receptor (CAR) to natural killer (NK) cells is garnering interest as a therapeutic strategy because this immune cell type doesn't cause graft-versus-host disease, making its widespread, off-the-shelf use feasible. Based on promising preclinical data, a phase I/II trial of one such CAR NK-cell therapy is under way, targeting CD19 in hematologic malignancies.
将嵌合抗原受体 (CAR) 添加到自然杀伤 (NK) 细胞中作为一种治疗策略引起了关注，因为这种免疫细胞类型不会引起移植物抗宿主病，使其广泛的、现成的使用成为可能。基于有前途的临床前数据，正在进行一项针对血液系统恶性肿瘤中 CD19 的此类 CARNK 细胞治疗的 I/II 期试验。
